

## Establishment of BALB/c Mice Model Infected With *Helicobacter pylori*

Dong Zhu Jin, M.D., Hyun Chae Jung, M.D., Jung Mogg Kim, M.D.\*  
Joo Sung Kim, M.D., In Sung Song, M.D. and Chung Yong Kim, M.D.

*Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine; Department of Microbiology and Institute of Biomedical Science, Hanyang University College of Medicine\*, Seoul, Korea*

**Objectives :** *Considering the geographic differences in the prevalence of virulence factors such as CagA or VacA of H. pylori isolated from Korean adults compared with those from western countries, the establishment of a mouse model infected with H. pylori isolated from Korean adults is needed to investigate the pathogenesis and to develop vaccines against H. pylori infection in Korea. The aim of this study was to establish the BALB/c mouse model infected with H. pylori isolated from Korean.*

**Methods :** *Six-week-old BALB/c mice were inoculated intragastrically with 10<sup>9</sup> CFU of H. pylori. Loss of glandular architecture, erosions and infiltration of inflammatory cells within the lamina propria compared with normal gastric mucosa were scrutinized. Evidence for H. pylori infection was assessed by rapid urease test of gastric mucosa and by microscopic examination using the H & E stain and Warthin-Starry silver stain.*

**Results :** *Rapid urease test was positive in 55% of all inoculated mice. Definite histologic changes and the evidence of H. pylori colonization were observed in the H. pylori infected group. Significant infiltration of inflammatory cells was observed 6 weeks after the last inoculation and the level of serum IgG against H. pylori was increased from 2 weeks after the last inoculation.*

**Conclusions :** *The H. pylori isolated freshly from Korean adults could colonize the stomach of BALB/c mice and induce pathologic alterations that mimics human gastric diseases. This model would facilitate the investigations for the pathogenetic mechanisms of H. pylori infection.*

**Key Words :** *Animal model, BALB/c mouse, H. pylori, Virulence factors*

### INTRODUCTION

*Helicobacter pylori* is now recognized as the major pathogenic factor for the development of chronic gastritis type B, peptic ulcer, and is strongly associated with gastric adenocarcinoma and lymphoma. *H. pylori* infection is a worldwide problem and more than 50%

of the world's population were infected with *H. pylori*. The prevalence of *H. pylori* infection in Korea was more than 70% of the population and virulence factors such as *cagA* or *vacA* of the *H. pylori* isolated from Korean adults revealed high levels compared with those from western countries<sup>1)</sup>.

To understand the pathogenesis of *H. pylori* infection and to develop novel therapies and vaccines, an adequate animal model to reproduce the various aspects of *H. pylori* disease is required. Early attempts to colonize rodents with *H. pylori* were unsuccessful<sup>2,3)</sup>. The first models of *H. pylori* infection were large animals such as gnotobiotic piglets<sup>4)</sup>,

---

Address reprint requests to : Hyun Chae Jung,  
Department of Internal Medicine and Liver Research  
Institute, Seoul National University College of Medicine,  
28 Yungon-dong, Chongno-gu, Seoul 110-792, Korea

monkeys<sup>5</sup>) and mice which do not express normal immune systems like euthymic germ-free mice<sup>6</sup>) and athymic nude mice<sup>7</sup>). These animal models can not be used easily to study immune response or to develop vaccines against *H. pylori* infection because they are more expensive and difficult for handling than small-sized animals, such as mice. *H. felis* or *H. mustalae*, which are different from *H. pylori*, have been used to infect mice<sup>8</sup>) or ferrets<sup>9</sup>), respectively. However, these animal models do not mimic *H. pylori* infection in man and subsequent pathologic features because those *Helicobacter* species do not have VacA and other virulence factors required for the induction of inflammation and ulcers<sup>10</sup>).

Recently, there has been some success in the development of a mouse model using human strains of *H. pylori*<sup>11, 12</sup>). Unfortunately, there has not been any report about the mouse model infected with *H. pylori* in Korea. Considering the geographic differences in the prevalence of virulence factors such as *cagA* or *vacA* of *H. pylori* isolated from Korean adults, compared with those from western countries<sup>1, 13, 14</sup>), the establishment of a mouse model infected with *H. pylori* isolated from Korean adults is needed to investigate the pathogenesis of *H. pylori* infection and to develop the vaccines. The present study describes the first attempt to establish a mouse model by direct inoculation of fresh *H. pylori* isolates to specific pathogen-free BALB/c mice without long-term adaptation.

## MATERIALS AND METHODS

### 1. Bacterial strains

*H. pylori* was isolated from the antral biopsy specimens of patients with duodenal ulcer at Seoul National University Hospital. Biopsy specimens were placed in Brucella broth (Difco Laboratories, Detroit, MI, USA) immediately and homogenized with a tissue grinder. The homogenate was then inoculated on selective agar [GC medium base (Difco Laboratories), 0.024% yeast extract, 1% hemoglobin, 1% IsoVitalX, 5 mg/L vancomycin, 1 mg/L mycostatin, 5% sheep blood]. The plates were incubated for 5-7 days at 37 °C under microaerophilic conditions (5% O<sub>2</sub>, 10% CO<sub>2</sub> and 85% N<sub>2</sub>) in a CO<sub>2</sub> incubator (Napco 5410, Tualatin, Oregon, USA). Pure culture isolates were examined by Gram stain and biochemical assay such as urease test<sup>14</sup>).

Isolates were finally confirmed as members of the genus *Helicobacter* by a polymerase chain reaction (PCR) as described below. For a long-term storage, isolates were stored in Brucella broth containing 15% (v/v) glycerol and kept at -70 °C.

### 2. Isolation of bacterial DNA

DNA was extracted from the *H. pylori* isolates with proteinase K, sodium dodecyl sulfate and hexadecyltrimethyl ammonium bromide (Sigma, St. Louis, MO, USA). The cell lysate was extracted in sequential steps with equal volumes of phenol, phenol chloroform/isoamylalcohol (25:24:1) and chloroform. DNA was then precipitated with isopropanol. The DNA pellet was washed with 70% ethanol, dried and resuspended in sterile Tris-EDTA buffer (pH 8.0).

### 3. RNA extraction and reverse transcription

Total RNA of *H. pylori* was extracted by the acid guanidinium thiocyanate-phenol-chloroform method<sup>15</sup>) (4 M guanidinium thiocyanate, 25 mM sodium citrate, pH 7.0; 0.4% sarcosyl, 0.1 M 2-mercaptoethanol). The RNA was dissolved in diethyl pyrocarbonate-treated distilled water, and quantitated at absorbance of 260 nm. One µg of each RNA of *H. pylori* isolated from human and mouse was used for single-strand cDNA synthesis with oligo(dT)<sub>18</sub> primer (Promega, Madison, WI, USA) and Moloney murine leukemia virus reverse transcriptase (Gibco BRL, Gaithersburg, MD, USA) as described previously<sup>16</sup>).

### 4. Polymerase chain reaction (PCR)

A number of PCRs were performed as described previously<sup>17</sup>) to characterize the *H. pylori* isolates obtained from humans or mice. These were *Helicobacter*-specific PCR, *ureA*, *cagA* and *vacA* PCRs and random amplified polymorphic DNA (RAPD) PCR<sup>18</sup>). Each PCR primer was designed on the basis of published sequences of *H. pylori*<sup>1, 16, 19, 20</sup>) as shown in Table 1. The primer sequence used for RAPD PCR was based on the publication by Lee et al.<sup>12</sup>) (5'-AACGCGCAAC-3'). Amplification of *H. pylori* genomic DNA sequences was carried out in a volume of 50 µl containing PCR buffer [50 mM KCl, 10 mM Tris-HCl (pH 8.3)], 1.5 mM MgCl<sub>2</sub>, 200 M dNTP, 0.5 M

**Table 1. Oligonucleotide primers and sizes of the PCR products for virulence factors of *H. pylori***

Gene		Primer sequence	Size of PCR product (bp)
<i>cagA</i>	S	5'-GATAACAGGCAAGCTTTTGAGG-3'	349
	AS	5'-CTGCAAAAGATTGTTTGGCAGA-3'	
<i>vacA1</i>	S	5'-ATGGAAATACAACAACACAC-3'	600
	AS	5'-CTCCAGAACCCACACGATT-3'	
<i>vacA3</i>	S	5'-TCAAAACCTTATTGATTGATAGCC-3'	600
	AS	5'-AAGCTTGATTGATCACTCC-3'	
<i>ureA</i>	S	5'-GCCAATGGAAATTAGTT-3'	491
	AS	5'-CTCCTTAATTGTTTTTAC-3'	
16S rRNA	S	5'-GCTAAGAGATCAGCCTATGTCC-3'	522
	AS	5'-TGGCAATCAGCGTCAGGTAATG-3'	

S: sense AS: antisense

primers, 2 U of Taq polymerase (Perkin-Elmer, Norwalk, CT, USA) and 100 ng of bacterial DNA or cDNA. Each reaction mixture was amplified for 33-39 cycles (shown in Table 2). In RAPD PCR, the MgCl<sub>2</sub> concentration was increased to 3 mmol/L and 20 pmol of a single primer was used. A sample omitting DNA or cDNA was included in every reaction as a negative control. Each PCR was performed with hot-start procedure<sup>21, 22</sup> and the final extension was performed at 72 °C for 10 min after the completion of the amplification cycles using a thermal cycler (Perkin Elmer). PCR products were separated in 2% NuSieve agarose gel (FMC Bioproducts, Rockland, ME, USA) and identified using ethidium bromide stains.

#### 5. Inoculation of mouse with *H. pylori*

Twenty-two, specific pathogen-free, 6-week-old female BALB/c mice were divided into two groups (4 of control and 18 of experiment). Three of frozen *cagA*<sup>-</sup>/*vacA*<sup>+</sup> *H. pylori* strains (strain # 99, # 232 and # 234) and one of fresh clinical *cagA*<sup>+</sup>/*vacA*<sup>+</sup> *H. pylori* isolates (strain # 7) were used in this study. Each *H. pylori* strain was cultured under microaerophilic conditions and was harvested in the sterile phosphate

buffered saline (PBS, pH7.4) and mixed by equal density. Mice were infected with the *H. pylori* mixture as described previously<sup>23</sup>. Briefly, all animals were fed on a commercial diet and given water *ad libitum*. Mice were fasted overnight except for water. Mice were inoculated intragastrically with 10<sup>9</sup> colony forming units (CFUs) of *H. pylori* mixture or PBS after treatment with 0.2 ml of 0.2 M NaHCO<sub>3</sub> intragastrically to neutralize gastric acidity. These procedures were repeated two or more times with a 2-day interval.

#### 6. Rapid urease test and histopathologic examination of gastric mucosa of mice

Mice were sacrificed 1, 2, 4 or 6 weeks after the last inoculation. The stomach of each mouse was bisected longitudinally. A specimen for rapid urease test (CLO test, Delta West Pty Ltd, Western Australia) was obtained from one half of the stomach and the remains of it were used for gastric scrapings for *H. pylori* cultures. They were fixed in buffered 10% formalin, using standard procedures, embedded in paraffin, sectioned at 4 μm, and stained with hematoxylin & eosin for histology and Wathin-Starry silver to assess the level of bacterial colonization<sup>24</sup>. The

**Table 2. PCR procedures for characterization of the *H. pylori* isolates**

	Thermal procedure	Cycles
<i>cagA</i> or 16S rRNA	94C: 1 min 55C: 1 min 72C: 1 min	39
<i>vacA</i> <sub>1, A<sub>2</sub> or A<sub>3</sub></sub>	95 : 30 sec 46 : 30 sec 72 : 30 sec	33
<i>ureA</i>	94 : 1 min 45 : 1 min 72 : 2 min	39
	94 : 5 min 40 : 5 min 72 : 5 min	5
RAPD	94 : 1 min 40 : 1 min 72 : 2 min	15
	94 : 1 min 36 : 1 min 72 : 2 min	15

glandular mucosae of the body, antrum and pylorus were examined histologically for a variety of inflammatory responses, epithelial changes and the presence of *H. pylori*.

#### 7. Enzyme linked immunosorbent assay (ELISA)

ELISA was performed for the assessment of immune response in *H. pylori*-infected mice as described previously<sup>25, 26)</sup> with minor modification. Briefly, to obtain the antigen to coat the microtiter plate, colonies of *H. pylori* were sonicated for three 30 sec bursts with 30 sec resting periods in an MSE Soniprep 150, and ultracentrifuged at 100,000 x g for 60 min (Beckman TL-100, Palo Alto, CA, USA). The antigen was diluted in 0.1 M carbonate buffer (pH 9.6) to a final concentration of 10 µg/ml. Microtiter plates were coated with 100 µl/well of antigen solution and

incubated overnight at 4 °C, washed three times with PBS containing 0.05% Tween-20 and then blocked with 200 µl/well of 1% bovine serum albumin in PBS/Tween-20 at room temperature for 2 hours. After washing the plates, 100 µl of each serum sample diluted 1:75 in PBS were added to wells in duplicate and the plates were incubated at room temperature for 2 hours. The plates were then washed three times and incubated with 100 µl/well of a goat anti-mouse IgG peroxidase conjugate (Pierce, Rockford, IL, USA) and diluted 1:700 in 1% BSA-PBS at room temperature for 2 hours. After three washings, 100 µl/well of a substrate solution containing p-nitrophenyl phosphate in diethanolamine-MgCl<sub>2</sub> buffer was added to each well. The reaction was stopped with 50 µl/well of 2 N H<sub>2</sub>SO<sub>4</sub>, and read the absorbance read using Wellscan microplate reader at OD450 nm (Dynatech MR 700, Alexandria, VA, USA).

## RESULTS

### 1. Infection rate after inoculation

Specific pathogen-free BALB/c female mice were inoculated with *H. pylori*. Mice were sacrificed 1, 2, 4 and 6 weeks after the last inoculation. Gastric specimens from infected mice were processed for urease test and histologic evaluation. The positivity of CLO tests in gastric specimens obtained from mice sacrificed one and two weeks after the last inoculation was only 40% but 75% in those from 4 and 6 weeks. (Table 3). As presented the above, the positivity of CLO test was gradually increased from 4 weeks after treatment with *H. pylori*, which indicates that the colonized *H. pylori* proliferated slowly and was located in the stomach. The CLO test in the control group was negative during the experimental period.

### 2. Histologic evaluation of gastric mucosa of mice infected with *H. pylori*


In the first week after the last inoculation, no definite presence of bacteria and infiltration of inflammatory cells were shown in *H. pylori*-infected group (Fig. 1). However, the inflammatory infiltrates of lymphocytes, plasma cells and polymorphonuclear leukocytes in the antrum and corpus mucosa were gradually increased from 2 weeks after the last inoculation of *H. pylori*. At

six weeks after the last inoculation, the gastric lesions were characterized by definite inflammatory infiltrates accompanied by the disruption of gastric architecture (Fig. 2,3) and distinct *H. pylori* colonization (Fig. 4). Control mice showed no evidence of significant infiltration of inflammatory cells during the entire experimental period (Fig. 5).

**Table 3. Results of the urease test and warthin-starry silver stain after inoculation of *H. pylori* in BALB/c mice**

	weeks after inoculation			
	1 (n=5)	2 (n=5)	4 (n=4)	6 (n=4)
Positive CLO test	2(40%)	2(40%)	3(75%)	3(75%)
Positive silver stain	0	1(20%)	1(20%)	2(40%)


n= numbers of mice inoculated with *H. pylori*/group



**Fig. 1.** Gastric mucosa of BALB/c mouse infected with *H. pylori* for 1 week. Significant infiltration of inflammatory cells is not seen. H & E stain. Original magnification, X 200.

### 3. Bacteria culture and PCR

Isolates from infected mice showed typical morphology and biochemical characteristics of *H. pylori* as the same as the original *H. pylori* strain (data not shown). Furthermore, the *Helicobacter*-specific PCR showed that the mouse and human isolates were identical to *H. pylori* (Fig. 6). The original human clinical isolates and the mouse isolates were also positive for *cagA* and *vacA* by PCR (Fig. 7). A comparison of the genomic DNA by RAPD PCR was performed for the



**Fig. 2.** Gastric mucosa of BALB/c mouse infected with *H. pylori* for 6 weeks. An extensive infiltration of inflammatory cells (arrow) is seen. H & E stain. Original magnification, X 200.




**Fig. 3.** Gastric mucosa of BALB/c mouse infected with *H. pylori* for 6 weeks. A definite destruction of gland architecture or loss of gastric glands (arrow) is seen. H & E stain. Original magnification, X 200.


mouse isolates and four original human clinical isolates which were used to infect the mouse. The mouse isolates gave an identical band pattern to only one (strain # 7) of the four human isolates (Fig. 8). These results suggest that strain # 7 may be the one that is able to colonize the mouse gastric mucosa among all the human isolates tested.

### 4. Serum antibody response to *H. pylori* infection

The experimentally infected mice showed serum antibody response to the colonizing strain that could be detected by an ELISA of mice sera from the first week of infection. Anti-*H. pylori* IgG antibody levels increased markedly from the second week after the last



**Fig. 4.** Gastric mucosa of BALB/c mouse infected with *H. pylori* for 6 weeks. Heavy colonization of *H. Pylori* and destruction of gland architecture (arrow) are seen. Warthin-Starry silver stain. Original magnification, X 400.




**Fig. 5.** Gastric mucosa of control BALB/c mouse. Infiltration of inflammatory cells is not seen and the architecture of the gland was well preserved. H & E stain. Original magnification, X 200.


inoculation with *H. pylori* and reached the plateau after the fourth week. In contrast, the negligible serum antibody response was shown in the control group during the entire experiment period (Fig. 9).

## DISCUSSION

*H. pylori* has been unambiguously implicated in the etiology of chronic gastritis and the recurrence of peptic ulceration in humans. Despite the high prevalence of *H. pylori* infection, serious gastric diseases characterized by gastric or duodenal ulcers are noted in a relatively small fraction of the *H. pylori*-infected population. To



**Fig. 6.** Characterization of *H. pylori* by PCR. *H. pylori* isolates (No. 7) from human (before inoculation to mouse) and mouse show identical pattern of *H. pylori*-specific 16S rRNA and *ureA* gene. Human (No. 99) was used as positive control. M: molecular marker ( X174/Hae ).



**Fig. 7.** Characterization of virulence factors of *H. pylori* by PCR. Each *H. pylori* strain isolated from human (before inoculation to mouse; lane 2, 3, 4, 5) and mouse (lane 6, 7, 8, 9) show identical pattern of virulence factors such as *vacA1*, *vacA2*, *vac3* and *cagA*. M: molecular marker ( X174/Hae ).

understand how *H. pylori* infects and occasionally causes serious diseases, and to investigate the immunologic mechanisms of *H. pylori* infection more precisely, it is necessary to develop the animal model infected with *H. pylori*. In the present study, we successfully established an animal model by oral challenges with a fresh *H. pylori* isolate to BALB/c mice without a long-term adaptation. Based on the result of urease tests, more than a half of the challenged mice were presumed to be infected by *H. pylori*. A striking feature of infection was the increasing serum IgG response against *H. pylori* sonicate antigen; infected mice showed a systemic




Fig. 8. DNA finger-printing of *H. pylori* before and after inoculation into mouse. *H. pylori* isolated from mouse (after inoculation) shows an identical pattern to only one (No. 7 that was fresh isolated) of four isolates inoculated (before inoculation into mouse). M1: molecular marker XI74/Hae<sup>3</sup>, M2: molecular marker DNA/Hind<sup>3</sup>.




Fig. 9. ELISA for serum IgG response to *H. pylori* sonicate antigen. Serum IgG reaction to *H. pylori* sonicate antigen became positive at 1 week post-inoculation and began to increase significantly at 2 weeks post-inoculation compared with that of control mice. Each panel represents the mean  $\pm$  SE of 3 separate experiments.

antibody response to the infected strain from the first week of infection. Serum IgG response was apparent in all mice by 6 weeks post-infection although the CLO positive was only 55% in all infected mice. We speculate that it may be due to a peculiar colonization pattern of *H. pylori* in gastric mucosa. *H. pylori* has acquired particular properties of colonization of the unique ecological niche on the surface of gastric epithelial cells and the distribution of *H. pylori* with associated inflammation are often patchy<sup>27, 28</sup>. Such a patchy distribution of *H. pylori*

colonization can lead to sampling error and subsequently, the false negative results of microscopic examination, culture and rapid urease test. Furthermore, the process of colonization with *H. pylori* in the gastric mucosa may take weeks<sup>29</sup>. The organism must enter the stomach, survive brief exposure to acid, traverse the mucous layer<sup>30</sup>, attach to epithelial cell receptors<sup>31</sup>, adapt its physiology to the hostile host environment and thereby establish its niche.

In this study, only the bacteria of a negligible number were found in the gastric antrum. However, the colonization with numerous bacteria was observed in the body and fore-stomach transition zones, accompanied with the disruption of gastric gland architecture. With light microscopy, the bacteria were observed in large numbers in the mucus overlying the epithelial cells and at the top of the gastric pits. It is closely similar to the colonizing pattern of *H. pylori* in humans. The infiltration of inflammatory cells, such as lymphocytes and plasma cells, in the antrum and corpus mucosa was gradually increased from 2 weeks after the last inoculation of *H. pylori*. In contrast, the infiltration of polymorphonuclear leukocytes was not prominent in the lamina propria until 4 weeks post-infection. However, it became evident at 6 weeks, although with only a few numbers.

In the present study, both *H. pylori* isolates from human (before inoculation to mouse) and mouse showed identical patterns of virulence factors such as *vacA1*, *vacA2*, *vacA3* and *cagA*. By RAPD PCR, the mouse isolate exhibited an identical band pattern to only one (fresh isolate # 7) of the four human isolates. This result suggests that the fresh isolate plays an important role in the colonizing process compared to long-term stored strains. Consecutive inoculation of ICR mice with *H. pylori* recovered from the stomach of BALB/c mice also showed systemic antibody response to the colonizing strain (data not shown).

The present study shows that a mouse model of *H. pylori* infection is successfully established. This model can be utilized for animal experiments of *H. pylori*, such as vaccine studies, screening for novel therapies, and investigation of the mechanisms of pathogenesis. Although some problems remain to be solved, such as to develop the strain with high colonizing ability and to examine a variety of mice strain, this mouse model will provide opportunities for studies on the interrelationship

between bacteria and the host with respect to colonization and the ecology of bacteria in the stomach. It will also facilitate investigations of the mechanisms of *H. pylori*-associated diseases, including peptic ulcer, gastric cancer and gastric lymphoma.

## REFERENCES

- Kim JM, Jung HC, Lee JY, Lee KM, Chin YJ, Kim YJ, Song IS, Kim CY. Prevalence of virulence factors in *Helicobacter pylori* isolated from Korean adults and proinflammatory cytokine gene expression in human gastric epithelial cells induced by *H. pylori* with virulence factors. *Korean J Med* 1998; 54:40-51.
- Ehlers S, Warelmann M, Hahn H. In search of an animal model for experimental *Campylobacter pylori* infection: administration of *Campylobacter pylori* to rodents. *Zentralbl Bakteriell Mikrobiol Hyg* 1988; 268: 341-346.
- Cantoma MF, Balish E. Inability of human clinical strains of *Helicobacter pylori* to colonize the alimentary tract of germ-free rodents. *Can J Microbiol* 1990; 36:237-241.
- Krakowka S, Morgan DR, Kraft WG, Leunk RD. Establishment of gastric *Campylobacter pylori* infection in the neonatal gnotobiotic piglet. *Infect Immun* 1987; 55:2789-2796.
- Euler AR, Zurenko GE, Moe JB, Ulrich RG, Yagi Y. Evaluation of two monkey species (*macaca mulatta* and *macaca fascicularis*) as possible models for human *Helicobacter pylori* disease. *J Clin Microbiol* 1990; 28:2285-2290.
- Karita M, Li Q, Cantero D, Okita K. Establishment of a small animal model for human *Helicobacter pylori* infection using germ-free mouse. *Am J Gastroenterol* 1994; 89:208-213.
- Tsuda M, Karita M, Morshed MG, Okita K, Nakazawa T. A urease-negative mutant of *Helicobacter pylori* constructed by allelic exchange mutagenesis lacks the ability to colonize the nude mouse stomach. *Infect Immun* 1994; 62:3586-3589.
- Lee A, Fox JG, Otto G, Murphy J. Small animal model of human *Helicobacter pylori* active chronic gastritis. *Gastroenterology* 1990; 99:1315-1323.
- Fox JG, Otto G, Murphy JC, Taylor NS, Lee A. Gastric colonization of the ferret with *Helicobacter* species; natural and experimental infections. *Rev Infect Dis* 1991; 13(suppl 8):S671-S680.
- Telford JL, Ghiara P, Dell'Orco M, Comanducci M, Burrioni D, Bugnoli M, Tecce MF, Censini S, Covacci A. Gene structure of the *Helicobacter pylori* cytotoxin and evidence of its key role in gastric disease. *J Exp Med* 1994; 179:1653-1658.
- Marchetti M, Arico B, Burrioni D, Figura N, Rappuoli R, Ghiara P. Development of a mouse model of *Helicobacter pylori* infection that mimics human disease. *Science* 1995; 267:1655-1658.
- Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, Dixon MF. A standardized mouse model of *Helicobacter pylori* infection: introducing the Sydney strain. *Gastroenterology* 1997; 112:1386-1397.
- Jung HC, Kim JM, Jin YJ, Lee KM, Kim WH, Song IS, Kim CY. Proinflammatory cytokine gene expression in human gastric epithelial cells induced by *H. pylori* according to virulence factors. *Korean J Gastroenterol* 1997; 29:579-590.
- Jung HC, Kim JM, Song IS, Kim CY. *Helicobacter pylori* induces an array of pro-inflammatory cytokines in human gastric epithelial cells: quantification of mRNA for interleukin-8, -1 $\beta$ , granulocyte-macrophage colony-stimulating factor, monocyte chemoattractant protein-1 and tumor necrosis factor- $\alpha$ . *J Gastroenterol Hepatol* 1997; 12:473-480.
- Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 1987; 162:156-159.
- Engstrand L, Nguyen AM, Graham DY, el-Zaatari FA. Reverse transcription and polymerase chain reaction amplification of rRNA for detection of *Helicobacter* species. *J Clin Microbiol* 1992; 30:2295-2301.
- Peek RM Jr, Miller GG, Tham KT, Perez-Perez GL, Cover TL, Atherton JC, Dunn GD, Blaser MJ. Detection of *Helicobacter pylori* gene expression in human gastric mucosa. *J Clin Microbiol* 1995; 33:28-32.
- van der Ende A, Rauws EA, Feller M, Mukler CJ, Tytgat GN, Dankert J. Heterogeneous *Helicobacter pylori* isolates from members of a family with a history of peptic ulcer disease. *Gastroenterology* 1996; 111: 638-647.
- Clayton CL, Kleanthous H, Coates PJ, Morgan DD, Tabaqchali S. Sensitive detection of *Helicobacter pylori* by using polymerase chain reaction. *J Clin Microbiol* 1992; 30:192-200.
- Tummuru MK, Cover TL, Blaser MJ. Cloning and expression of a high-molecular-mass major antigen of *Helicobacter pylori*: evidence of linkage to cytotoxin production. *Infect Immun* 1993; 61:1799-1809.
- Kim JM, Jung HC, Cho YJ, Kim CY. Interleukin-8 gene expression in the human gastric epithelial cells infected with *Helicobacter pylori*. *J Korean Soc Microbiol* 1995; 4:391-402.
- Kim JM, Jung HC, Cho YJ, Song IS, Kim CY. Expression of proinflammatory cytokine gene in the human gastric epithelial cells infected with *Helicobacter pylori*: Quantitation of mRNA of proinflammatory cytokines. *J Korean Soc Microbiol* 1995; 6:651-663.
- Ghiara P, Marchetti M, Blaser MJ, Tummuru MK, Cover TL, Segal ED, Tompkins LS, Rappuoli R. Role of the *Helicobacter pylori* virulence factors vacuolating



- cytotoxin, CagA, and urease in a mouse model of disease. *Infect Immun* 1995; 63:4154-4160.
24. Humphreys H, O'Morain C. Culture of the organisms and histochemical identification. *Scand J Gastroenterol Suppl* 1988; 142:16-20.
25. Jung HC, Choi SW, Song YW, Song IS, Kim CY. Detection of *Campylobacter pylori* and significance of serum IgG antibody to *Campylobacter pylori* in patients with peptic ulcer, erosive gastritis and non-ulcer dyspepsia. *Korean J Gastroenterol* 1988; 20:47-56.
26. Perez-Perez GI, Dworkin BM, Chodos JE, Blaser MJ. *Campylobacter pylori* antibodies in humans. *Ann Intern Med* 1988; 109:11-17.
27. Wyatt JJ, Primrose J, Dixon MF. Distribution of *Campylobacter pylori* in gastric biopsies. *J Pathol* 1988; 155:350A.
28. Morris A, Ali MR, Brown P, Lane M, Patton K. *Campylobacter pylori* infection in biopsy specimens of gastric antrum: laboratory diagnosis and estimation of sampling error. *J Clin Pathol* 1989; 42:727-732.
29. Mobley HLT. Defining *Helicobacter pylori* as a pathogen: strain heterogeneity and virulence. *Am J Med* 1996; 20(suppl 5A):S2-S11.
30. Jung HC, Kim JM, Song IS, Kim CY. Increased motility of *Helicobacter pylori* by methylcellulose could up-regulate the expression of proinflammatory cytokines in human gastric epithelial cells. *Scand J Clin Lab Invest* 1997; 57:263-270.
31. Fan X, Crowe SE, Behar S, Gunasena H, Ye G, Haeberle H, Van Houten N, Gourley WK, Ernst PB, Reyes VE. The effect of class II major histocompatibility complex expression on adherence of *Helicobacter pylori* and induction of apoptosis in gastric epithelial cells: a mechanism for T helper cell type 1-mediated damage. *J Exp Med* 1998; 187:1659-1669.
-